This information is intended for Colorado Prescribers
HB 19-1131
|
MARKETED PRESCRIPTION DRUG |
COLORADO WAC DISCLOSURE FORM |
DATE UPDATED |
|---|---|---|
|
Diabetes Products |
1/4/2022 |
|
|
Vaccines |
5/11/2022 |
|
|
ALDURAZYME® (laronidase) |
1/19/2022 |
|
|
ALPROLIX® [Coagulation factor IX (recombinant), Fc fusion protein] |
1/4/2022 |
|
|
AUBAGIO® (teriflunomide) |
1/4/2022 |
|
|
CABLIVI® (caplacizumab-yhdp) |
1/4/2022 |
|
|
CERDELGA® (eliglustat) capsules, for oral use |
1/19/2022 |
|
|
Cerezyme® (imiglucerase) for injection |
1/19/2022 |
|
|
DUPIXENT® (dupilumab) Injection |
4/3/2022 |
|
|
ELITEK® (rasburicase) for injection |
1/4/2022 |
|
|
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] |
1/4/2022 |
|
|
ENJAYMO™ (sutimlimab-jome) injection, for intravenous use |
2/17/2022 |
|
|
FABRAZYME® (agalsidase beta) for injection, for intravenous use |
1/19/2022 |
|
|
JEVTANA® (cabazitaxel) Injection |
1/4/2022 |
|
|
KEVZARA® (sarilumab) |
1/4/2022 |
|
|
LEMTRADA® (alemtuzumab) |
1/4/2022 |
|
|
LIBTAYO® (cemiplimab - rwlc) |
5/13/2022 |
|
|
LOVENOX® (enoxaparin sodium injection) |
1/19/2022 |
|
|
LUMIZYME® (alglucosidase alfa) |
1/19/2022 |
|
|
Mozobil® (plerixafor injection) |
1/4/2022 |
|
|
MULTAQ® (dronedarone) |
1/4/2022 |
|
|
NEXVIAZYME (avalglucosidase alfa-ngpt) for injection, for intravenous use |
1/19/2022 |
|
|
REZUROCK® (belumosudil) tablets |
5/1/2022 |
|
|
SARCLISA® (isatuximab-irfc) injection |
1/4/2022 |
|
|
Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)] |
1/4/2022 |
|
|
THYROGEN® (thyrotropin alfa for injection) |
1/19/2022 |
House Bill 19-1131. Published by the General Assembly of the State of Colorado
Please See Full Prescribing Information, including Boxed Warning, for Aldurazyme, Aubagio, Elitek, Jevtana, Kevzara, Lemtrada, Lovenox, Lumizyme, Multaq,
Nexviazyme, Thymoglobulin
MAT-US-2007971-v5.0-05/2022
Last update: May 2022